VivoSim Labs Inc VIVS Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.14 up $0.00, 0.07% at close Nov 6
Last close · Previous close $0.14
- Market cap
- At the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$0.14down $0.06, 29.87%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.14Nov 5
- Volume167.48KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.02MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.14 to $3.40; now $0.14
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
VIVS trailed the S&P 500 in all 7 periods.
| Period | VIVS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | VIVS: down 29.9% S&P 500: down 5.6% | VIVS trailed the S&P 500 by 24.3 percentage points Trailed |
| 3M | VIVS: down 57.1% S&P 500: down 4.1% | VIVS trailed the S&P 500 by 53.0 percentage points Trailed |
| YTD | VIVS: down 92.2% S&P 500: up 8.7% | VIVS trailed the S&P 500 by 100.9 percentage points Trailed |
| 1Y | VIVS: down 93.5% S&P 500: up 10.9% | VIVS trailed the S&P 500 by 104.4 percentage points Trailed |
| Long term | ||
| 3Y | VIVS: down 99.2% S&P 500: up 75.0% −79.7% vs +20.5% a year | VIVS trailed the S&P 500 by 174.2 percentage points Trailed |
| 5Y | VIVS: down 99.8% S&P 500: up 67.8% −71.3% vs +10.9% a year | VIVS trailed the S&P 500 by 167.6 percentage points Trailed |
| 10Y | VIVS: down 100.0% S&P 500: up 313.1% −57.1% vs +15.2% a year | VIVS trailed the S&P 500 by 413.1 percentage points Trailed |
$10,000 invested in VIVS 10 years ago (Nov 4, 2016) would be worth about $2 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
VIVS trailed the S&P 500 in all 7 periods.
| Period | VIVS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | VIVS: down 29.9% S&P 500: down 5.6% | VIVS trailed the S&P 500 by 24.3 percentage points Trailed |
| 3M | VIVS: down 57.1% S&P 500: down 4.3% | VIVS trailed the S&P 500 by 52.8 percentage points Trailed |
| YTD | VIVS: down 92.2% S&P 500: up 7.8% | VIVS trailed the S&P 500 by 100.0 percentage points Trailed |
| 1Y | VIVS: down 93.5% S&P 500: up 9.7% | VIVS trailed the S&P 500 by 103.2 percentage points Trailed |
| Long term | ||
| 3Y | VIVS: down 99.2% S&P 500: up 68.8% −79.7% vs +19.1% a year | VIVS trailed the S&P 500 by 168.0 percentage points Trailed |
| 5Y | VIVS: down 99.8% S&P 500: up 56.9% −71.3% vs +9.4% a year | VIVS trailed the S&P 500 by 156.7 percentage points Trailed |
| 10Y | VIVS: down 100.0% S&P 500: up 252.6% −57.1% vs +13.4% a year | VIVS trailed the S&P 500 by 352.6 percentage points Trailed |
$10,000 invested in VIVS 10 years ago (Nov 4, 2016) would be worth about $2 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$3,060.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Feb 14, 2012.
Stock splits
2
Latest: 1-for-12 on . Share counts adjust after each split.
Both splits
- 1-for-12
- 1-for-20
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q1 FY27, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $112.00Kdown 21.1%
- Net income
- −$12.34M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY25 (Sep 30, 2024) | $30.00K | −$2.55M | Paused See the note under the price. |
| Q3 FY25 (Dec 31, 2024) | $24.00K | −$3.45M | Paused See the note under the price. |
| Q4 FY25 (Mar 31, 2025) | $51.00K | $6.85M | Paused See the note under the price. |
| Q1 FY26 (Jun 30, 2025) | $37.00K | −$2.84M | Paused See the note under the price. |
| Q2 FY26 (Sep 30, 2025) | $28.00K | −$2.55M | Paused See the note under the price. |
| Q3 FY26 (Dec 31, 2025) | $26.00K | −$2.69M | Paused See the note under the price. |
| Q4 FY26 (Mar 31, 2026) | $40.00K | −$5.76M | Paused See the note under the price. |
| Q1 FY27 (Jun 30, 2026) | $18.00K | −$1.34M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY22 (Mar 31, 2022) | $1.50M | −$11.45M | Paused See the note under the price. |
| FY23 (Mar 31, 2023) | $370.00K | −$17.26M | Paused See the note under the price. |
| FY24 (Mar 31, 2024) | $109.00K | −$14.67M | Paused See the note under the price. |
| FY25 (Mar 31, 2025) | $144.00K | −$2.49M | Paused See the note under the price. |
| FY26 (Mar 31, 2026) | $131.00K | −$13.84M | Paused See the note under the price. |
Margins
- Gross 100.0%
- Operating −10,117.0%
- Net −11,016.1%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$10.12MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$10.10MLast 12 months
- Capital spending$23.00KLast 12 months
- −9,038.4%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $3.00MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $1.81MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$316.00KAs of Jun 30, 2026
- Net cash$1.50MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 1.70As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- 3 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −612.2%Last 12 months
Over the last 12 months, VivoSim Labs lost money: its net loss was 612.2% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −177.0%Last 12 months
Over the last 12 months, VivoSim Labs’s net loss was 177.0% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About VivoSim Labs Inc
Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development. The company’s lead molecule, FXR314, is on the path for Phase 2 investigation in inflammatory bowel disease and has potential application in metabolic liver disease and oncology. The company has proprietary technology used to build 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
VIVS news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
VIVS stock FAQ
What is VIVS stock’s price today?
VivoSim Labs (VIVS) traded at $0.14 at the close on , unchanged from the previous close of $0.14. Over the past 52 weeks it has traded between $0.14 and $3.40.
If you invested $1,000 in VIVS 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in VIVS on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $2 if invested five years ago and $65 if invested one year ago. Past performance doesn’t predict future returns.
How much revenue does VivoSim Labs make?
VivoSim Labs reported $112.0 thousand of revenue over the four quarters to , down 21.1% from the twelve months before. In its latest quarter (Q1 FY27, ended ) revenue was $18.0 thousand, down 51.4% from a year earlier.
Is VivoSim Labs profitable?
Not over the four quarters to . VivoSim Labs reported a net loss of $12.3 million across those four quarters on $112.0 thousand of revenue.
Does VIVS pay a dividend?
VivoSim Labs hasn’t paid a dividend in the last twelve months.
What is VIVS’s 52-week high and low?
Over the past 52 weeks VIVS has traded as low as $0.14 and as high as $3.40. At $0.14 at the close on , it is 95.8% below that high and 4.3% above the low.
What is VIVS’s all-time high?
VIVS’s highest closing price was $3,060.00 on , adjusted for stock splits. At $0.14 at the close on , it is 100.0% below that record.
Has VIVS stock ever split?
Yes, twice: 1-for-20 on ; 1-for-12 on .
How has VIVS stock performed?
Including dividends and measured to the close on , VIVS has returned −92.2% so far this year and −93.5% over the past year, and −99.8% over five years (−71.3% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is VivoSim Labs in?
VivoSim Labs is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does VIVS trade on?
VivoSim Labs trades on the Nasdaq under the ticker symbol VIVS. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.